申请人:ZERIA PHARMACEUTICAL CO., LTD.
公开号:EP0424528A1
公开(公告)日:1991-05-02
Drugs for improving cerebral circulation, cerebral metabolism and memory containing as the active ingredient a phenylalkanoylamine derivative or its salt represented by general formula (I) (wherein A represents a 1,3-thiazolin-3-yl group, a 1,2,3,6-tetrahydropyridin-1-yl group, a morpholino group, a thiomorpholin-4-yl group or a 3-pyrrolin-1-yl group, R¹ and R² may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group, an amino group or (α) (wherein R³ and R⁴ each represents a lower alkyl group or, when taken together, they represent a 5- or 6-membered heterocyclic group together with the nitrogen atom), and n represents an integer of 2 to 6) and novel phenylalkanoylamine derivatives among the compounds represented by (I), and a process for their preparation are disclosed. The above drugs are useful for treating sequelae of cerebral hemorrhage, sequelae of cerebral infarction, arterial aclerosis of brain, sequelae of subarachnoidal hemorrhage, sequelae of head trauma, sequelae of cerebral operation, dementia of cerebral vessel origin, Parkinson's disease, Alzheimer's disease, Pick's disease, sequelae of hypoxia, alcoholic cerebral diseases, etc.
改善脑循环、脑代谢和记忆的药物,其活性成分含有通式(I)代表的苯基烷酰基胺衍
生物或其盐(其中A代表1,3-
噻唑啉-3-基、
1,2,3,6-四氢吡啶-1-基、吗啉基、
硫代吗啉-4-基或
3-吡咯啉-1-基,R¹和R²可以相同或不同,各自代表氢原子、(α)(其中 R³ 和 R⁴ 各自代表一个低级烷基,或当它们结合在一起时,与氮原子一起代表一个 5 或 6 元杂环基团),且 n 代表 2 至 6 的整数)和(I)所代表的化合物中的新型苯基烷酰基胺衍
生物及其制备方法。上述药物可用于治疗脑出血后遗症、脑梗塞后遗症、脑动脉硬化、蛛网膜下腔出血后遗症、头部外伤后遗症、脑手术后遗症、脑血管源性痴呆、帕
金森病、阿尔茨海默病、皮克病、缺氧后遗症、
酒精性脑病等。